Literature DB >> 109914

Gold and thiol compounds in the treatment of rheumatoid arthritis: excretory fate and tissue distribution of thiomalate in relation to gold after administration of myocrisin (auro-thiomalate).

E Jellum, E Munthe, G Guldal, J Aaseth.   

Abstract

Double isotope-labelled auro thiomalate (Au195-C14-thiomalate) has been administered to mice and rats, and the excretory fate and tissue distribution have been studied. The results show that the gold and the thiomalate separate in vivo resulting in protein-bound gold and release of free thiomalate. About half of this thiol is excreted in the urine during the first day and the remaining half is taken up by the tissues. Thiomalate penetrates cellular membranes poorly, but is able to interact slowly with proteins (mixed disulphide formation). Part of the thiomalate which remains in the body is membrane bound. In contrast to penicillamine little thiomalate remains in circulation a few hours after administration. Gas chromatography--mass spectrometry has been used to search for the presence of free thiomalate in rheumatoid arthritis patients on Myocrisin (auro thiomalate) therapy. Thiomalate was found in their urine, but not in serum and synovial fluid 20 hours after administration. As thiomalate is released in the body after administration of Myocrisin. the question arises whether this thiol, like penicillamine, may have a beneficial effect in the treatment of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 109914

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  4 in total

1.  Cultured human cells with high levels of gold-binding cytosolic metallothionein are not resistant to the growth inhibitory effect of sodium aurothiomalate.

Authors:  A Glennås; H E Rugstad
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

2.  Role of metallothionein in cellular uptake and disposition of gold sodium thiomalate.

Authors:  R P Sharma
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

Review 3.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

4.  Fate of the thiomalate part after intramuscular administration of aurothiomalate in rheumatoid arthritis.

Authors:  E Jellum; E Munthe
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.